Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.
Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a rare multisystemic congenital myopathy that mainly affects males, and which is incompletely understood genetically speaking.
Vantai Inc. has entered into an amended and restated collaboration and license agreement with Blueprint Medicines Corp. to design and advance novel targeted protein degrader therapies.
Corbus Pharmaceuticals Holdings Inc. has obtained FDA clearance of its IND application for CRB-601, a TGF-β-blocking monoclonal antibody targeting the integrin αvβ8. Enrollment in a first-in-human phase I study will open in the first half of this year.
There is a strong relationship between heart failure (HF) and atrial fibrillation (AF): half of the patients with HF acquire AF. Recent studies discovered a genetic basis underlying AF, which demonstrated a strong heritable component to this disease.
RSS
